Aventis Launches Preservative Free Vaccine for Tetanus and Diphtheria

Document Sample
Aventis Launches Preservative Free Vaccine for Tetanus and Diphtheria Powered By Docstoc
					                                       Aventis Launches Preservative-Free Vaccine
                                       for Tetanus and Diphtheria

                                         We are pleased to announce the availability of
                                         DECAVAC™ (Tetanus and Diphtheria Toxoids
                                         Adsorbed For Adult Use), the company’s recently
                                         licensed preservative-free tetanus and diphtheria
                                         (Td) vaccine. DECAVAC vaccine is formulated
                                         without preservatives; only a trace amount of
                                         thimerosal (≤0.3 µg mercury per dose) remains
                                         from the manufacturing process. As the nation’s
major supplier of Td vaccine, Aventis Pasteur, the vaccines business of the sanofi-aventis
Group, is dedicated to maintaining public confidence in vaccines and ensuring a smooth
transition for customers from the traditional Td vaccine to the new preservative-free
DECAVAC vaccine.

Health-care providers can place orders for DECAVAC vaccine on-line at
www.vaccineshoppe.com or by calling 1-800-VACCINE (1-800-822-2463).

DECAVAC vaccine contains the same tetanus and diphtheria components utilized in
Aventis Pasteur’s previous Td vaccine, but now it is supplied preservative-free in a
single-dose, prefilled syringe. DECAVAC vaccine is indicated for use as a routine
booster every 10 years throughout life for persons seven years of age or older who have
received a primary series of tetanus- and diphtheria-containing vaccine. It is also used
for wound care in persons who have not received a tetanus toxoid-containing preparation
within the preceding five years.

While 80% of Americans aged 12 to 19 have protective levels of antibodies to fight these
two diseases, just 47% of adults over 20 years of age are protected.1 Therefore, it is
important to be aware of the vaccination status for all of your adolescent and adult
patients and make sure they get the tetanus-diphtheria booster immunization every 10
years to stay protected.

Aventis Pasteur decided several years ago to pursue preservative-free formulations. The
launch of DECAVAC vaccine is an example of this commitment.

The preservative thimerosal is used in the production process for many vaccines. There
are trace amounts of thimerosal left over from the production process that cannot be
removed, but these amounts are so small that the Food and Drug Administration, US
Centers for Disease Control and Prevention and the Institute of Medicine consider
DECAVAC vaccine to be preservative-free.

Safety Information
There are risks associated with all vaccines, including DECAVAC™ (Tetanus and
Diphtheria Toxoids Adsorbed For Adult Use). The most common local adverse reactions
associated with Td may include erythema (redness), tenderness, and swelling at the
injection site. Common systemic reactions may include headache, malaise, and
temperature elevations. Additional adverse reactions reported between 1998-2003 during
post-approval use of Td vaccine include local reactions at injection site (swelling,
redness, warmth, cellulitis), myalgia, arthralgia, muscle stiffness, nausea, vomiting,
paraesthesia, dizziness, convulsions, and rash. Arthus-type hypersensitivity reactions,
characterized by severe local reactions (generally starting 2.8 hours after an injection),
may follow receipt of tetanus toxoid. Persistent nodules at the site of injection have been
reported following the use of adsorbed products. More serious adverse reactions may
occur but are rare. DECAVAC vaccine is contraindicated in patients with
hypersensitivity to any component of the vaccine. As with any vaccine, vaccination with
DECAVAC vaccine may not protect 100% of individuals.

For full prescribing information, see the DECAVAC vaccine package insert at

To unsubscribe from TdUpdate, respond to this e-mail with the word "unsubscribe" in the
subject line. Anyone interested in subscribing to TdUpdate may do so by e-mailing
tdupdate@aventis.com with the word "subscribe" in the subject line. We also value your
input; comments and suggestions can be addressed to tdupdate@aventis.com or
submitted by replying to this e-mail. Aventis Pasteur, Inc., Discovery Drive, Swiftwater,
PA 18370.

 McQuillan GM, Kruszon-Moran D, Deforest A, Chu Sy, and Wharton M, Serologic Immunity to Diphtheria and
Tetanus in the United States, Annals of Internal Medicine, May 7, 2002, vol 136, p. 660.

Shared By:
Description: Aventis Launches Preservative Free Vaccine for Tetanus and Diphtheria